ArticleVeterinary research2012
Characterization of homologous and heterologous adaptive immune responses in porcine reproductive and respiratory syndrome virus infection.
Article in Veterinary research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.
- Systematic review of animal-based indicators to measure thermal, social, and immune-related stress in pigs.PloS one · 2022Pooled it
- Trial
- Comparison of the efficacy of autogenous inactivated Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccines with that of commercial vaccines against homologous and heterologous challenges.BMC veterinary research · 2012Trial
- TNF-α and IL-10 differentially modulate apoptosis during PRRSV-1 infection of bone marrow-derived dendritic cells.BMC veterinary research · 2026Article
- Cross-Protection in PRRSV: Mechanisms, Limitations, and Implications for Vaccine Design.Pathogens (Basel, Switzerland) · 2026Review
- Cross-protection conferred by intradermal PRRSV-1 modified live vaccine against a highly virulent Vietnamese PRRSV-2 strain in pigs.Frontiers in veterinary science · 2026Article
- Translating viral genetic data to PRRSV-2 cross-neutralization using machine learning.Frontiers in immunology · 2026Article
- Evaluation of the infectivity of three porcine reproductive and respiratory syndrome virus (PRRSV) variants.Veterinary research · 2025Article
- Immunopathological features of highly pathogenic Korean Lineage B PRRSV-2: insights into virulence indicators and host immune responses.Frontiers in immunology · 2025Article
- A chimeric porcine reproductive and respiratory syndrome virus 1 strain containing synthetic ORF2-6 genes can trigger T follicular helper cell and heterologous neutralizing antibody responses and confer enhanced cross-protection.Veterinary research · 2024Article
- Levels of neutralizing antibodies against resident farm strain or vaccine strain are not indicators of protection against PRRSV-1 vertical transmission under farm conditions.BMC veterinary research · 2023Article
- Testable Candidate Immune Correlates of Protection for Porcine Reproductive and Respiratory Syndrome Virus Vaccination.Vaccines · 2023Review
- Infection dynamics, transmission, and evolution after an outbreak of porcine reproductive and respiratory syndrome virus.Frontiers in microbiology · 2023Article
- Insight into the Economic Effects of a Severe Korean PRRSV1 Outbreak in a Farrow-to-Nursery Farm.Animals : an open access journal from MDPI · 2022Article
- The Swine IFN System in Viral Infections: Major Advances and Translational Prospects.Pathogens (Basel, Switzerland) · 2022Review
- Heterologous vaccine immunogenicity, efficacy, and immune correlates of protection of a modified-live virus porcine reproductive and respiratory syndrome virus vaccine.Frontiers in microbiology · 2022Article
- Aberrant long non-coding RNA cancer susceptibility 15 (CASC15) plays a diagnostic biomarker and regulates inflammatory reaction in neonatal sepsis.Bioengineered · 2021Article
- Reappraisal of PRRS Immune Control Strategies: The Way Forward.Pathogens (Basel, Switzerland) · 2021Review
- Phylogenetic Structure and Sequential Dominance of Sub-Lineages of PRRSV Type-2 Lineage 1 in the United States.Vaccines · 2021Article
- The Ability of Porcine Reproductive and Respiratory Syndrome Virus Isolates to Induce Broadly Reactive Neutralizing Antibodies Correlates WithFrontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study characterized the homologous and heterologous immune response in type-I porcine reproductive and respiratory syndrome virus (PRRSV) infection. Two experiments were conducted: in experiment 1, eight pigs were inoculated with PRRSV strain 3262 and 84 days post-inoculation (dpi) they were challenged with either strain 3262 or strain 3267 and followed for the next 14 days (98 dpi). In experiment 2, eight pigs were inoculated with strain 3267 and challenged at 84 dpi as above. Clinical course, viremia, humoral response (neutralizing and non-neutralizing antibodies, NA) and virus-specific IFN-γ responses (ELISPOT) were evaluated all throughout the study. Serum levels of IL-1, IL-6, IL-8, TNF-α and TGF-β were determined (ELISA) after the second challenge. In experiment 1 primo-inoculation with strain 3262 induced viremia of ≤ 28 days, low titres of homologous NA but strong IFN-γ responses. In contrast, strain 3267 induced longer viremias (up to 56 days), higher NA titres (≤ 6 log2) and lower IFN-γ responses. Inoculation with 3267 produced higher serum IL-8 levels. After the re-challenge at 84 dpi, pigs in experiment 1 developed mostly a one week viremia regardless of the strain used. In experiment 2, neither the homologous nor the heterologous challenge resulted in detectable viremia although PRRSV was present in tonsils of some animals. Homologous re-inoculation with 3267 produced elevated TGF-β levels in serum for 7-14 days but this did not occur with the heterologous re-inoculation. In conclusion, inoculation with different PRRSV strains result in different virological and immunological outcomes and in different degrees of homologous and heterologous protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.